Merck’s ongoing pneumococcal vaccine development program is designed to provide options that address the specific needs of different populations, including infants and children, healthy adults ...

Related: What Is Pneumococcal Meningitis? Merck’s first pneumonia vaccine, Pneumovax 23, received FDA approval in 1983, and ...

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...

Prior to COVID-19, pneumococcal vaccines were the largest vaccine market worldwide – estimated at around $8 billion – with Prevnar capturing almost $6 billion of that total in 2020 from its ...

Although Merck’s vaccine, like Pfizer’s, is approved for use in people at least 18 years of age, Capvaxive is the only pneumococcal disease vaccine that was specifically made to protect adults ...

Merck already sells an older pneumococcal vaccine called Pneumovax 23, which protects against 23 strains but is a polysaccharide based shot, so doesn't stimulate as strong an immune response as ...

CAPVAXIVE is Merck's approved 21-valent pneumococcal conjugate vaccine indicated for active immunization for the prevention of invasive disease and pneumonia in adults 18 years of age and older.

U.S. health officials on Wednesday recommended that people 50 and older get a shot against bacteria that can cause pneumonia and other dangerous illnesses. The recommendation was made by a scientific ...

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

Merck reports Q3 sales of $16.7 billion, up 4% year-over-year, with Keytruda revenue rising 17%. EPS beats estimates; 2024 guidance updated on global demand shifts.

In June this year, the FDA approved Merck’s Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) to protect against 21 strains of bacteria to prevent a severe form of pneumococcal disease.